Heller K S, Attie J N
Department of Surgery, Long Island Jewish Medical Center, New Hyde Park, New York.
Am J Surg. 1988 Oct;156(4):294-6. doi: 10.1016/s0002-9610(88)80295-2.
Among 162 patients with Warthin's tumor, 113 had removal by enucleation. The others, in whom parotidectomy and facial nerve dissection were performed, were not suspected of having Warthin's tumor preoperatively or had tumor too close to the facial nerve to be safely enucleated. Patients were generally older and more likely to be male than patients with other benign parotid tumors. Fifteen patients had multiple Warthin's tumors at the time of initial presentation; in an additional 12 patients, Warthin's tumor developed in the opposite parotid gland after the initial operation. In only two patients did an additional tumor develop in a gland from which a Warthin's tumor had previously been enucleated. No permanent injuries to the facial nerve occurred. Because of the safety and efficacy with which enucleation can be performed and because the risk of malignant transformation of Warthin's tumors is extremely small, we believe that enucleation is the treatment of choice in most cases.
在162例沃辛瘤患者中，113例行剜除术切除肿瘤。其余患者因术前未怀疑患有沃辛瘤或肿瘤距面神经过近无法安全剜除而接受了腮腺切除术及面神经解剖术。与其他腮腺良性肿瘤患者相比，沃辛瘤患者通常年龄更大，男性更为多见。15例患者初诊时即有多发沃辛瘤；另有12例患者在初次手术后对侧腮腺发生了沃辛瘤。仅有2例患者在先前已行沃辛瘤剜除术的腺体中又出现了新的肿瘤。未发生面神经永久性损伤。鉴于剜除术的安全性和有效性，以及沃辛瘤恶变风险极低，我们认为在大多数情况下，剜除术是首选的治疗方法。
